Natural history of ‘second’ biochemical failure after salvage radiation therapy for prostate cancer: a multi‐institution study by Tumati, Vasu et al.
Natural history of ‘second’ biochemical failure
after salvage radiation therapy for prostate
cancer: a multi-institution study
Vasu Tumati*, William C. Jackson†, Ahmed E. Abugharib†, Ganesh Raj‡,
Claus Roehrborn‡, Yair Lotan‡, Kevin Courtney§, Aditya Bagrodia‡, Jeffrey C. Gahan‡,
Zachary S. Zumsteg**, Michael R. Folkert*, Aaron M. Laine*, Raquibul Hannan*,
Daniel E. Spratt† and Neil B. Desai*
Departments of *Radiation Oncology, ‡Urology, §Internal Medicine, University of Texas Southwestern Medical Center,
Dallas, TX, USA, Department of †Radiation Oncology, University of Michigan, Ann Arbor, MI, USA, and **Department
of Radiation Oncology Cedars-Sinai Medical Center, Los Angeles, CA, USA
V. T. and W.C.J. are equal first authors.
D.E.S. and N.B.D. are equal senior authors.
Objectives
To describe the natural history of prostate cancer in men
who experience a second biochemical recurrence (BCR) after
salvage radiotherapy (SRT) after prostatectomy.
Patients and Methods
After undergoing SRT at one of two institutions between
1986 and 2013, 286 patients experienced a second BCR,
defined as two rises in prostate-specific antigen (PSA) of
≥0.2 ng/mL above nadir. Event rates for distant metastasis
(DM) or freedom from DM (FFDM), castration-resistant
prostate cancer (CRPC), prostate cancer-specific survival
(PCSS), and overall survival (OS) were estimated using the
Kaplan–Meier method. Cox regression was used for
comparative analyses.
Results
At a median of 6.1 years after second BCR, DM, CRPC,
PCSS and OS rates were 41%, 27%, 83% and 73%,
respectively. On multivariable analysis, interval to second
BCR <1 year (hazard ratio [HR] 2.66, 95% confidence
interval [CI] 1.71–4.14; P < 0.001], Gleason score 8–10 (HR
1.65, 95% CI 1.07–2.54; P = 0.022), and concurrent ADT
during SRT (HR 1.76, 95% CI 1.08–2.88; P = 0.024) were
associated with FFDM, while PCSS was associated with
interval to second BCR <1 year (HR 3.00, 95% CI 1.69–5.32;
P < 0.001) and concurrent ADT during SRT (HR 2.15, CI
1.13–4.08; P = 0.019). These risk factors were used to stratify
patients into three groups, with 6-year FFDM rates of 71%,
59% and 33%, and PCSS rates of 89%, 79%, and 65%,
respectively.
Conclusion
Following second BCR after SRT, clinical progression is
enriched in a subgroup of patients with prostate cancer, while
others remain without DM for long intervals. Stratifying
patients into risk groups using prognostic factors may aid
counselling and future trial design.
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Introduction
Adjuvant postoperative radiotherapy (RT) is effective in
reducing biochemical recurrence (BCR) when radical
prostatectomy (RP) reveals adverse pathological features
[1–5]; however, a strategy of salvage radiotherapy (SRT) after
post-RP BCR is more commonly used [6–8]. At the time of
SRT, the poor sensitivity of existing imaging for excluding
occult micrometastasis and heterogeneous patient
presentation contribute to a significant rate of subsequent
treatment failure or ‘second’ BCR [3,5,9,10].
While the natural history of patients who experience BCR
after definitive RT and RP alone has been described [11–15],
detailed outcomes of patients who experienced BCR after
postoperative RT are largely limited to the adjuvant setting
[14,15]. Because SRT occurs at varying intervals of up to
several years from RP, it cannot be assumed that second BCR
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after SRT confers the same risk of clinical progression to
metastasis or death when compared with BCR after definitive
RT, RP, or even adjuvant postoperative RT. Data specific to
this cohort of patients with second BCR after SRT is needed
to facilitate patient counselling and inform trial design.
To determine the natural history and predictors of outcomes
in patients who experience BCR after SRT, we performed a
multi-institutional retrospective study in patients who
received SRT and experienced second BCR.
Methods
Patient Cohort
After obtaining institutional review board approval, a
retrospective review was conducted of 571 patients treated for
prostate cancer between 1986 and 2013 who underwent SRT
after RP at two large institutions (University of Texas
Southwestern Medical Center and the University of
Michigan). SRT was defined as receipt of postoperative RT
for a rising PSA level or SRT performed at least 4 months
after RP in the absence of data on PSA. Of the patients who
received SRT, only those who subsequently experienced BCR
were included in the present study. BCR after postoperative
RT was defined using the AUA definition of a PSA rise of
≥0.2 ng/mL above nadir with a sequential equal or higher
value, yielding 286 patients who formed the study cohort.
All the patients were treated with curative intent RP with
limited lymph node sampling, without routine use of
extended lymph node dissection. Those patients with high
risk features were treated at their physician’s discretion with
RT to pelvic lymph nodes and/or with concurrent androgen
deprivation therapy (ADT). RT was generally delivered by
three-dimensional conformal radiation planning until 2004 at
both institutions, after which intensity-modulated RT was
routine. Total radiation dose varied modestly (interquartile
range [IQR] 64.8–68.4 Gy) according to era of treatment,
physician discretion and institutional preference. Typical
follow-up included testing of PSA and of testosterone in
those who received ADT, and physical examination. Imaging
was not routinely obtained unless there was evidence of
biochemical failure or clinical progression.
Analyses
After SRT, local recurrence was defined by imaging or DRE,
regional failure by pelvic lymph node involvement on
imaging, and distant metastasis (DM) by imaging without
requirement of pathological confirmation (almost exclusively
by CT and technetium bone scan, with the minority receiving
MRI or positron-emission tomography). Castration resistance
was defined as two or more successive rises in PSA level,
despite testosterone level <50 ng/mL, or evidence of clinical
progression of disease despite the use of ADT, similar to the
PSA working group definition [16]. Estimates of rates of local
recurrence, regional recurrence, freedom from DM (FFDM)
or, conversely, DM, prostate cancer-specific survival (PCSS),
and overall survival (OS) were calculated using the Kaplan–
Meier method from the time of ‘second’ BCR after SRT.
Groups were compared using the log-rank test.
Univariable and multivariable analyses were performed
using Cox regression methods to identify the
clinicopathological variables affecting progression to DM
and PCSS. Studied variables included interval to BCR
(>1 year vs ≤1 year) from RP, nodal involvement, Gleason
grade, T stage, pre-SRT PSA level, and margin status. PSA
doubling time was not considered sufficiently robust for
analysis because of the low values at time of SRT and lack
of multiple measures prior to SRT in many patients. RT
dose and/or use of intensity-modulated RT planning were
not analysed because of small absolute dose changes (IQR
64.8–68.4 Gy), low isolated recurrence rates after SRT with
‘lower’ doses in a prospective study [10], confounded
association of SRT dose with institution in our dataset, and
lack of granular data on planning technique for all
patients. For those factors found to be prognostic on
multivariable analysis for DM or PCSS, we generated risk
groupings based on the number of and specific risk factors
present. To account for the differing contributions of each
prognostic risk factor in our multivariable model for FFDM
specifically, the relative influence of the individual risk
factors was weighted according to their hazard ratios
[HRs]. Specifically, a risk score for an endpoint was
generated based on summing the HRs of each prognostic
variable harboured by a patient for the particular endpoint,
and the resulting sums were used to generate groupings
(Table S1). Analyses were conducted using IBM SPSS v.23
(SPSS Inc., Chicago, IL, USA). An a value of 0.05 was




The study assessed 286 patients who experienced second BCR
after SRT. The median follow-up after second BCR was
6.1 years. Comprehensive demographics and treatment details
are included in Table 1. A small majority of patients,
constituting the present cohort, was treated between 2000
and 2009 (54.9%). The median (IQR) pre-RT PSA level was
0.6 (0.3–1.1) ng/mL, 139 patients (48.6%) had a PSA ≤
0.5 ng/mL, 92 (32.1%) had Gleason score ≥8, 172 (60.1%)
had stage ≥pT3, and the median (IQR) RT dose was 66.6
(64.8–68.4) Gy. Only 18.5% of patients received concurrent
ADT with SRT. SRT dose was not associated with time era
of treatment (P = 0.857) but was associated with institution
(P < 0.001).
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Outcomes
For patients who experienced second BCR after SRT, the
median (IQR) time to second BCR was 16 (6–38) months.
For those patients treated with concurrent ADT, the
median time to second BCR was 16 months, which was
not significantly different from the median 15 months to
second BCR for those not receiving ADT (log-rank
P = 0.232). After second BCR, 6-year local and regional
recurrence rates were 4.9% and 7.5%, respectively. The
6-year rates of DM and development of castration-resistant
prostate cancer (CRPC) after second BCR were 41.1% and
27.4%, respectively (Fig. 1A). The median FFDM time from
second BCR was 112 months. The 6-year rates of PCSS
and OS from second BCR were 82.5% and 72.9%,
respectively, with a median PCSS not reached and a
median OS time of 158 months (Fig. 1B and C). The
majority of patients with second BCR subsequently received
ADT (n = 193, 68%). Of the 79 patients who developed
CRPC, the proportions of patients with additional therapy
exposure were as follows: enzalutamide 24.1%;
abiraterone 45.6%; docetaxel 65.8%; cabazitaxel 10.1%;
radionuclide therapy 7.6%; and sipuleucel-T 3.8%. Multiple
lines of therapy were received by 35% of patients with
CRPC.
Of the 116 patients who developed DM, the median (IQR)
time to DM was 36 (10.5–66) months from second BCR.
The median OS time from initial metastasis was 62 months.
Because not all patients developed metastasis, we sought to
determine the risk features associated with FFDM after
second BCR (Table 2). Interval to second BCR <1 year (6-
year FFDM 48% vs 67%; P < 0.001), stage ≥pT3 (6-year
FFDM 66% vs 54%; P = 0.012), Gleason score 8–10 (6-year
FFDM 39% vs 68%; P < 0.001), pre-RT PSA > 0.5 ng/mL
(6-year FFDM 55% vs 63%; P = 0.011), and concurrent
ADT (6-year FFDM 63% vs 44%; P = 0.001) were each
associated with worse FFDM after second BCR on
univariable analyses. Pathological node positivity (P = 0.132)
approached significant association with FFDM and was
included in the multivariable model. On multivariable
analysis, interval to second BCR <1 year (HR 2.66, 95% CI
1.71–4.14; P < 0.001), Gleason score 8–10 (HR 1.65, 95% CI
1.07–2.54; P = 0.022), and concurrent ADT (HR 1.76, 95%
CI 1.08–2.88; P = 0.024) remained significantly predictive of
FFDM after second BCR (Table 2). We additionally used
these features to generate risk groups for development of
DM after second BCR. As the HR for interval to second
BCR <1 year was substantially higher than that for Gleason
8–10 or concurrent ADT, this risk grouping relied on
weighting of risk factors according to their HRs, as shown
in Table S1. In this manner, patients could be stratified into
three groups: group 1 (0 factors or either concurrent ADT
or Gleason ≥ 8 only); group 2 (interval to BCR < 1 year);
or group 3 (any two or more risk factors), as shown in
Fig. 2A, with 6-year FFDM rates from second BCR of 71%,
59% and 33%, respectively. The proportions of patients in
groups 1, 2 and 3 in this schema were 54%, 24% and 22%,
respectively.
We similarly examined prognostic factors for PCSS after
second BCR in this patient cohort, of whom 54 patients
died from prostate cancer (Table 2). On univariable analysis,
interval to second BCR <1 year (89% vs 74%; P < 0.001),
pre-SRT PSA ≤ 0.5 ng/mL (HR 1.62, 95% CI 1.15–3.30; P =
0.013), and concurrent ADT (HR 1.87, 95% CI 1.01–3.46; P
= 0.046) were associated with worse PCSS. Gleason score 8–
10 (P = 0.136) approached significant association with worse
PCSS and thus was included in the multivariable analysis.
On multivariable analysis, interval to second BCR <1 year
(HR 3.00, 95% CI 1.69–5.32; P < 0.001) and concurrent
ADT (HR 2.15, 95% CI 1.13–4.08; P = 0.019) remained
significantly associated with PCSS. These prognostic features
again were used to generate risk groupings. Specifically, in
Table 1 Patient demographics.
Characteristic All patients Patients with
second BCR
Median (range) follow-up, months 82 (1–269) 98 (1–269)
Median (range) age, years 63 (29–84) 63 (39–840
Median (range) PSA, pre-RP 7.7 (0–120) 8 (0–120)
Median (range) PSA, pre-SRT 0.4 (0–17.4) 0.6 (0–11.93)
Gleason score, n (%)
≤6 82 (14.4) 33 (11.5)
3 + 4 180 (31.5) 62 (21.7)
4 + 3 143 (25.0) 88 (30.8)
8 67 (11.7) 40 (14.0)
9 83 (14.5) 51 (17.8)
10 1 (0.2) 1 (0.3)
Unknown 15 (2.6) 11 (3.8)
pT-Stage
T2 253 (44.3) 105 (36.7)
T3 297 (52.0) 169 (59.1)
T4 6 (1.1) 3 (1.0)
Unknown 15 (2.6) 9 (3.1)
pN stage
N0 479 (83.9) 235 (82.2)
N1 28 (4.9) 14 (4.9)
Nx 64 (11.2) 37 (12.9)
Margin
Positive 322 (56.4) 136 (47.6)
Negative 228 (39.9) 137 (47.9)
Unknown 21 (3.7) 13 (4.5)
Concurrent ADT
Yes 129 (22.6) 53 (18.5)
No 442 (77.4) 233 (81.5)
Whole pelvic RT
Yes 99 (17.3) 40 (14.0)
No 472 (82.7) 246 (86.0)
Decade of Treatment
1986–1989 10 (1.8) 8 (2.8)
1990–1999 153 (26.8) 97 (33.9)
2000–2009 321 (56.2) 157 (54.9)
2010–2013 85 (14.9) 23 (8.0)
ADT, androgen deprivation therapy; BCR, biochemical recurrence; RP, radical
prostatectomy; RT, radiotherapy; SRT, salvage radiotherapy.
© 2017 The Authors
BJU International © 2017 BJU International 367
Natural history of postoperative radiation therapy failure
patients with 0, 1 or 2 risk factors, 6-year PCSS rates were
89%, 79% and 65%, respectively (Fig. 2B). The proportion of
patients with 0, 1 or 2 risk factors was 48%, 46% and 7%,
respectively.
Discussion
Determining the natural history of men with second BCR
after SRT is important for counselling patients and in
directing subsequent therapy. A significant body of literature
details the outcomes of postoperative RT and of untreated
BCR after RP or definitive RT [5,8,11–14,17–19]; however,
the specific prognosis at time of second BCR after SRT
remains poorly described.
As second BCR after SRT represents an exhaustion of local
therapy sometimes years after initial RP, one might expect
rapid subsequent clinical progression to metastasis and
related death; however, median time to DM from second
BCR and median OS from second BCR were >9 years and
13 years, respectively. Allowing for differences in reporting,
these intervals compare favourably with outcomes in most
series of BCR after initial local therapy, including definitive
RT, RP alone or RP with adjuvant RT (Table 3) [11,12,14].
They are also consistent with previously reported outcomes in
patients experiencing a ‘first’ BCR after adjuvant
postoperative RT [14,15].
The retention of a long interval to detection of metastasis
after second BCR in the present series is potentially
attributable to underestimation of early ADT interventions
and the limited sensitivity of traditional imaging. Second, the
median pre-RT PSA level of 0.4 ng/mL in our screening
cohort of 571 patients undergoing SRT reflects the results of
a transition to an ‘early’ SRT approach, which is associated
with improved DM-free survival and PCSS rates [18,20].
Third, the apparently better outcome of patients in second
BCR after SRT in our series compared with initial BCR after
definitive RT [11] is probably attributable to the different and
more sensitive definition of second BCR after SRT (confirmed
rise ≥0.2 ng/mL above nadir after SRT compared with nadir
+ 2 mg/mL after definitive RT). Nonetheless, given the
interesting similarity of outcomes in our series to natural
history series of initial BCR failure after RP [12,13], one may
speculate whether survival has been improved and the disease
timeline fundamentally shifted even in these patients
ultimately failing SRT.
While these suggested benefits of SRT and long median
natural histories are noted, 41% of patients still experienced
DM, and the majority were initiated either before or after
DM on ADT. In the present study, presence of rapid second
BCR after SRT (<1 year), high Gleason grade (8–10), or
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Fig. 1 Kaplan–Meier plots with numbers at risk for patients with biochemical failure after salvage radiotherapy for (A) freedom from distant metastasis,
(B) prostate cancer-specific survival and (C) overall survival.
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multivariable analysis for DM risk. Similarly, studies of the
natural history of RP, dose-escalated external-beam RT, and
postoperative RT have shown that short interval to failure
were significant predictors of DM [11,12,15,19], as well as
prostate cancer-specific mortality [21,22]. Further, in an
analysis of 134 patients with BCR after adjuvant RT by
Boorjan et al. [14], Gleason score was predictive of DM.
While lower pre-RT PSA level has been associated with
improved clinical outcomes after SRT in several series
[18,20,23] including our own [24], we did not find that pre-
RT PSA remained predictive of outcomes for those with
second BCR, probably as a result of fundamentally different
determinants of natural history at this time point (i.e. speed
of micrometastatic disease progression as opposed to
likelihood of cure by SRT). Similarly, while some
retrospective SRT series have found a benefit to dose
escalation [25–27], in our dataset, the range of SRT dose was
small and confounded by association with institution (not
significantly associated with FFDM or PCSS after second BCR
when adjusting for institution; data not shown), precluding its
analysis. In part, this was because of the study focus on those
with second BCR with long follow-up; a minority of patients
were treated after 2010 when higher SRT doses might be
expected. Because isolated locoregional relapse rates in both
the present study and prospective SRT data [10] were
infrequently detected, however, it is also likely that SRT dose
has no effect on those who experience second BCR, where
prognosis appears dominated by other metastasis.
Identification of those at highest risk for progression to DM
may help inform trial design in this area and spare overly
aggressive management in those at lower risk with competing
risks. To this end, we proposed a risk stratification model at
time of second BCR after SRT. For instance, study of early
cytotoxic therapy, such as docetaxel, in the setting of recent
data on its benefit in earlier metastatic and non-metastatic
states [28,29] may be focused on patients fitting our group 2
or 3 risk categories, whose significant progression rates make
feasible a 5-year FFDM endpoint.
The 6-year 18% rate of prostate cancer related-death was
similarly spread across patients in a heterogeneous manner
and in significant association with a short interval to BCR
<1 year and/or failure despite concurrent ADT, both of
which have previously been associated with PCSS in various
contexts [15,19,30,31]. Interestingly, second BCR despite
concurrent ADT with SRT was associated with both
decreased FFDM and PCSS, which is probably a reflection of
poor disease biology and/or delay in detecting second BCR
because of the prolonged suppressive effect of ADT on PSA
level, particularly for GnRH agonists. Notably, those patients
who fail aggressive definitive therapy, including ADT, have
previously been suggested to be intrinsically at higher risk of
DM and CRPC [31]. Given the level 1 data on the benefit of
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would not be appropriate to hypothesize whether use of ADT
itself plays a causative role in early clinical progression
amongst those experiencing second BCR. More practically, in
the present study, we quantified risk groups for PCSS
according to interval to second BCR and failure despite use of
concurrent ADT with SRT, which should facilitate selection
of patients for systemic therapy salvage trials according to
their relative risk of death from disease.
The present study has several limitations. First, the
retrospective nature of the study limits interpretation of
reasons for imaging and therapeutic interventions after BCR.
Second, over the long time period of the study, several
changes occurred in the management of prostate cancer, such
as increasing use of RP in high-risk patients, use of early SRT
and addition of concurrent ADT, all of which may
fundamentally alter the prognosis of patients at time of
second BCR in more contemporary patients. In this same
vein, as several therapies for CRPC have been introduced
since 2010, PCSS would be expected to be prolonged in
contemporary patients, as compared with the majority of
patients in our study treated before 2010. Conversely, the
introduction of more sensitive imaging is likely to affect time
at DM detection and time from DM to CRPC and death—an
arguably landscape-changing effect in prostate cancer natural
history analysis for which we were unable to account. In
addition, PSA doubling time, a previously suggested correlate
of DM and PCSS in various settings, could not be analysed at
time of second BCR after SRT because of the low PSA values
at SRT and lack of multiple measures prior to SRT in many
patients.
Nonetheless, this study is the largest to examine specifically
the outcomes of patients who experienced second BCR
after SRT. We show that, while many of these patients
have prolonged survival, a significant proportion is enriched
for DM and ensuing morbidity and mortality. High
Gleason grade, failure despite concurrent ADT with SRT,
or short intervals to BCR appear to predict those patients
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Fig. 2 Risk groupings for patients with second biochemical failure after
salvage radiotherapy (SRT) for (A) freedom from metastasis with
stratification based on presence of Gleason 8–10 pathology, interval to
second biochemical relapse <1 year, or failure despite concurrent
androgen deprivation therapy (ADT) with SRT and (B) prostate cancer-
specific survival with stratification based on presence of interval to second
biochemical failure <1 year, and/or biochemical recurrence despite
concurrent ADT with SRT.





Median PCSS, years Median OS,
years
Current Study (postoperative RT
second BCR)
297 6 9.3 (6-year DM 41%) Not reached (6-year PCSS 83%) 13.1 (6-year OS 73%)
RP/adjuvant RT first BCR
(Boorjan et al. [14])†
134 8 Not reached (15-year DM 45%) Not reached (15-year PCCS 65%) Not reported
RP/adjuvant RT first BCR
(Abdollah et al. [15])
336 5.3 Not reported Not reached (10-year PCSS 79%) Not reported
EBRT first BCR (Zumsteg et al. [11] 609 4.8 5.4 (5-year DM 47%) 10.5 (5-year PCSS 82%) Not reported
RP first BCR (Johns Hopkins) [13,19] 450* 8* 10 (10-year DM 52%)* Not reached (10-year PCSS 73%)* Not reported
BCR, biochemical recurrence; DM, distant metastasis; EBRT, external beam radiotherapy; OS, overall survival; PCSS, prostate cancer-specific survival; RP, radical prostatectomy; RT,
radiotherapy. *BCR after RP defined as PSA ≥0.2 ng/mL above nadir, median follow-up and DM-free survival reported from Antonarakis et al. [13], PCSS from Freedland et al.
[19]. †BCR after RP defined as PSA 0.4 ≥ ng/mL.
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particular. The resultant stratification of risk within this
heterogeneous population may help with the clinical trial
design of new systemic therapy approaches, such as early
ADT or docetaxel, and identify populations for early re-
staging imaging with novel ligand positron-emission
tomography to identify low burden metastatic states, which
may be amenable to novel strategies, such as stereotactic
ablative RT [33].
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